A lternative splicing is an important posttranscriptional regulatory mechanism through which pre-mRNA molecules can produce multiple distinct mRNAs. Alternative splicing affects over 95% of human genes 1 , contributing to the functional diversity and complexity of proteins expressed in tissues 2 . Alternative splicing is abundant in human nervous system tissues 3 and contributes to phenotypic differences within and between individuals: at least 20% of disease-causing mutations may affect pre-mRNA splicing 4 . Mutations in RNA-binding proteins (RBPs) involved in splicing regulation and aberrant splicing have been linked to amyotrophic lateral sclerosis 5 and autism 6 . Furthermore, disruptions in RNA metabolism, including mRNA splicing, are associated with age-related disorders, such as frontotemporal lobar dementia 7 , Parkinson's disease 8 and Alzheimer's disease 9,10 . These previous studies have mostly focused on alternative splicing of selected candidate genes, including the amyloid precursor protein (APP) 8 and microtubule-associated protein tau (MAPT) 8, 9, 11 . However, proteomic profiles of brains from patients with Alzheimer's disease identified increased aggregation of insoluble U1 snRNP, a small nuclear RNA component of the spliceosomal complex, suggesting that the core splicing machinery may be altered in Alzheimer's disease 12 . Apart from these studies, there have been few investigations of the possibility that more widespread splicing disruption affects brain transcriptomes in Alzheimer's disease 13 . However, a comprehensive study of cis-and trans-acting genetic factors that regulate alternative splicing in aging brains is lacking.
A lternative splicing is an important posttranscriptional regulatory mechanism through which pre-mRNA molecules can produce multiple distinct mRNAs. Alternative splicing affects over 95% of human genes 1 , contributing to the functional diversity and complexity of proteins expressed in tissues 2 . Alternative splicing is abundant in human nervous system tissues 3 and contributes to phenotypic differences within and between individuals: at least 20% of disease-causing mutations may affect pre-mRNA splicing 4 . Mutations in RNA-binding proteins (RBPs) involved in splicing regulation and aberrant splicing have been linked to amyotrophic lateral sclerosis 5 and autism 6 . Furthermore, disruptions in RNA metabolism, including mRNA splicing, are associated with age-related disorders, such as frontotemporal lobar dementia 7 , Parkinson's disease 8 and Alzheimer's disease 9, 10 . These previous studies have mostly focused on alternative splicing of selected candidate genes, including the amyloid precursor protein (APP) 8 and microtubule-associated protein tau (MAPT) 8, 9, 11 . However, proteomic profiles of brains from patients with Alzheimer's disease identified increased aggregation of insoluble U1 snRNP, a small nuclear RNA component of the spliceosomal complex, suggesting that the core splicing machinery may be altered in Alzheimer's disease 12 . Apart from these studies, there have been few investigations of the possibility that more widespread splicing disruption affects brain transcriptomes in Alzheimer's disease 13 . However, a comprehensive study of cis-and trans-acting genetic factors that regulate alternative splicing in aging brains is lacking.
Over 24 genetic loci have now been associated with Alzheimer's disease susceptibility by genome-wide association studies (GWAS) 14 , and these variants are enriched for associations with gene expression levels in peripheral myeloid cells and often lie within cisregulatory elements 15 . For example, we reported that one of these variants influences splicing of CD33 16 . Given the high abundance of alternative splicing in the brain, we hypothesized that other genetic variants associated with Alzheimer's disease could also affect pre-mRNA splicing, possibly by disrupting efficient binding of splicing factors.
Here, by applying state-of-the-art analytic methods, we generated a comprehensive genome-wide map of splicing variation in the aging prefrontal cortex. We use this map to identify: (1) aberrant mRNA splicing events related to Alzheimer's disease; (2) a new reference of thousands of genetic variants influencing local mRNA splicing in the brain; (3) trans-acting splicing factors that are involved in intron excision; and (4) association of GWAS findings to specific genes within each Alzheimer's disease susceptibility locus. Overall, we deepen our understanding of genetic regulation in the transcriptome of the aging brain and provide a foundation for Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer's disease susceptibility Towfique Raj 1,2 *, Yang I. Li 3 , Garrett Wong 1,2 , Jack Humphrey 4,5 , Minghui Wang 2 , Satesh Ramdhani 1,2 , Ying-Chih Wang 2 , Bernard Ng 6,7 , Ishaan Gupta 1 , Vahram Haroutunian 8,9 , Eric E. Schadt 2 , Tracy Young-Pearse 10 , Sara Mostafavi 6,7 , Bin Zhang 2 , Pamela Sklar 2,8 , David A. Bennett 11 and Philip L. De Jager 12,13 * Here we use deep sequencing to identify sources of variation in mRNA splicing in the dorsolateral prefrontal cortex (DLPFC) of 450 subjects from two aging cohorts. Hundreds of aberrant pre-mRNA splicing events are reproducibly associated with Alzheimer's disease. We also generate a catalog of splicing quantitative trait loci (sQTL) effects: splicing of 3,006 genes is influenced by genetic variation. We report that altered splicing is the mechanism for the effects of the PICALM, CLU and PTK2B susceptibility alleles. Furthermore, we performed a transcriptome-wide association study and identified 21 genes with significant associations with Alzheimer's disease, many of which are found in known loci, whereas 8 are in novel loci. These results highlight the convergence of old and new genes associated with Alzheimer's disease in autophagy-lysosomal-related pathways. Overall, this study of the transcriptome of the aging brain provides evidence that dysregulation of mRNA splicing is a feature of Alzheimer's disease and is, in some cases, genetically driven.
Results
Aberrant mRNA splicing in Alzheimer's disease. We deeply sequenced RNA from frozen DLPFC samples obtained at autopsy from 450 participants of either the Religious Order Study (ROS) or the Memory and Aging Project (MAP), two prospective cohort studies of aging that include brain donation. All subjects were without known dementia at study entry. During the study, some subjects experienced cognitive decline, and, at autopsy, they displayed a range of amyloid-β and tau pathology, with 60% of subjects having a pathologic diagnosis of Alzheimer's disease 17, 18 (Supplementary  Table 1 ). We have previously reported changes in RNA expression level in relation to Alzheimer's disease in these data 19 .
Following alignment and quantification of RNA-sequencing (RNA-seq) reads, LeafCutter 20 was applied to estimate the 'percentage spliced-in' values (PSI) for local alternative splicing events ( Fig. 1 ). We identified 53,251 alternatively spliced intronic excision clusters in 16,557 genes. We report more alternatively spliced intron clusters in the cortex than any other previously analyzed tissues or brain regions 21 . To identify aberrant splicing events, we analyzed the association between the PSI of each intron excision event and a pathologic diagnosis of Alzheimer's disease or quantitative analyses of neuropathology, including neuritic plaques, neurofibrillary tangles and amyloid-β burden, while accounting for confounding factors. At a false-discovery rate (FDR) < 0.05, we identified a total of 82 differentially spliced introns in 67 genes associated with different neuropathologies, including 5 associated with neuritic plaques, 20 associated with amyloid-β burden and 48 with neurofibrillary tangles (Supplementary Table 2 ). A heat map of the top differentially spliced introns associated with neurofibrillary tangles is shown in Fig. 2a . On average, these differentially excised introns explain around 2-13% of total variation in neuropathologic burden after accounting for biological and technical covariates ( Fig. 2b and Supplementary Fig. 1 ).
To test for association with the clinical diagnosis of Alzheimer's disease, we used LeafCutter 20 to identify differentially spliced introns by jointly modeling intron clusters using a Dirichletmultinomial generalized linear model (Methods). At a Bonferronicorrected rate of P < 0.05, we identified a total of 87 intron clusters (corresponding to 84 genes) that displayed altered splicing in relation to Alzheimer's disease ( Supplementary Table 3 ). Of these, 11 genes were also differentially expressed, suggesting that our splicing analysis is identifying novel associations that had been missed in conventional approaches evaluating gene expression levels alone. For example, the most significant differentially excised intron (chr10:3,147,351-3,147,585) is found in the phosphofructokinase gene (PFKP): the frequency of this splicing event was associated with Alzheimer's disease (P < 4.9 × 10 −24 ; β = − 0.27) and all pathologic analyses that were tested in this study. Similarly, the next most differentially excised intron (chr14:21,490,656-21,491,400) associated with Alzheimer's disease is found in the α /β -hydrolase fold protein gene NDRG family member 2 (NDRG2) (P < 5.6 × 10 −19 ; β = − 0.058) and is also associated with measures of both amyloid-β and tau pathology ( Fig. 2c ). Differential splicing of both PFKP and RNA was sequenced from the gray matter of the DLPFC of 542 samples (450 remained after quality control and matching for genotype data) from the ROS/MAP cohort. RNA-seq data were processed, aligned and quantified by our parallelized pipeline. The intronic usage ratios for each cluster were then computed using LeafCutter 20 , standardized (across individuals) and quantile normalized. The intronic usage ratios were used for differential splicing analysis, for calling sQTLs and for TWAS. TWAS was performed on summary statistics from IGAP Alzheimer's disease (AD) GWAS of 74,046 individuals 14 .
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NDRG2 in human brains has been previously shown to be associated with Alzheimer's disease pathogenesis 22, 23 , offering a measure of replication. Other genes with differentially excised introns associated with Alzheimer's disease at a Bonferroni-corrected P < 0.05 include APP (P < 1.6 × 10 −3 ; β = − 0.003) and genes in known GWAS loci such as PICALM (P < 0.02; β = 0.005) and CLU (P < 3.2 × 10 −4 ; β = − 0.019). These differentially spliced genes are not necessarily expressed in a single cell type (for example, neurons), but are expressed across many cell types, including astrocytes ( Supplementary Figs. 2, 3 and Supplementary Table 4 ). Moreover, co-splicing network analysis using WGCNA 24 suggests that the differentially spliced genes are enriched in specific functional modules and are part of a coherent biological process (Supplementary  Figs. 2, 3, Supplementary Tables 5-7 and Supplementary Note) . Next, to assess the robustness of our results, we performed a replication analysis using RNA-seq data from the Mount Sinai Brain Bank (MSBB) 25 , which includes 301 brain samples from patients with Alzheimer's disease and controls (Supplementary Note). Of the 84 genes with differentially spliced intron clusters in ROS/ MAP, 52 (including APP, PFKP and NDRG2) were significant at a Bonferroni-corrected P < 0.05 threshold in the MSBB data and the effect sizes are highly correlated between the two datasets (Pearson's r = 0.35; P < 6.75 × 10 −14 ) ( Fig. 2c , Supplementary Fig. 4 and Supplementary Table 8 ). This constitutes an independent replication of specific, aberrant splicing alterations in brains from patients with Alzheimer's disease. Finally, to further validate and explore the mechanism of our observations, we analyzed RNA-seq data derived from induced pluripotent stem cell (iPSC)-derived neurons and neurons from the same line overexpressing tau: differential intron excision was noted for 42 genes (FDR < 0.05), of which 11 genes overlap with the Alzheimer's disease-associated splicing in the cortex including APP, PICALM and NDRG2 ( Fig. 2d and Supplementary Table 9 ). Despite the small sample size, these in vitro data suggest that tau accumulation in neurons-at a stage in which neurons are accumulating phosphorylated tau but are not apoptotic-may be sufficient to induce some of the splicing alterations that we observed in cortical tissue of human subjects; this in vitro validation of disease-related splicing changes suggests that this Alzheimer's disease-altered splicing (1) is unlikely to be related to confounding factors from autopsy or the agonal state and (2) has specific target RNAs that can be modeled in vitro.
Genetic effects on pre-mRNA splicing in aging brains. We next performed a sQTL study to identify local genetic effects that drive 
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NATuRe GeNeTiCs variation in RNA splicing in the DLPFC. First, we assessed the splice events from the LeafCutter 20 algorithm ( Fig. 1 ); 30% of these 53,251 intron excision clusters are novel splicing events, not previously reported in other sQTL studies. The PSI values were adjusted for known and hidden factors (15 principal components) and then fit to imputed SNP data using an additive linear model implemented in fastQTL 26 (Methods and Supplementary Fig. 5 ). At FDR < 0.05, we found 9,028 sQTLs in 3,006 genes (Supplementary Table 10 ). As expected, splicing was most strongly affected by variants in the splice region itself (59.8%): 20.2% of variants are mapped to splice acceptor sites and 16.4% to splice donor sites. The remaining (23.2%) mapped to other splice regions or are found within an intron ( Supplementary Fig. 6 ). Furthermore, sQTLs are mapped to distinct regulatory features as defined by 15 chromatin states in DLPFC 27 : sQTLs were significantly enriched in actively transcribed regions and enhancers. They are depleted in repressed chromatin marked with polycomb, heterochromatin and quiescent regions ( Fig. 3a) , consistent with the diminished transcription noted in these regions.
To assess the extent of sQTL replication, we compared our sQTLs to the recently published dataset from the CommonMind Consortium (CMC), consisting of DLPFC profiles from 258 individuals with schizophrenia and 279 control subjects 28 (Supplementary Note). Our sQTLs yield a Storey's π 1 = 0.78 in the CMC data, suggesting substantial sharing of sQTLs between these two different brain collections (Fig. 3b ). Moreover, 93% of shared sQTLs showed the same direction of effect (Fig. 3b ). The fraction of novel sQTLs deserves further evaluation to assess the extent to which they may be context-specific given that the average age at death of our participants (88 years) is significantly older than that of the CMC dataset.
In agreement with recent findings in lymphoblastoid cell lines 21 , we found that a majority of sQTLs act independent of gene expression effects, as evident by the low degree of sharing between sQTLs and expression (e)QTLs 29 from the same brains (π 1 = 0.18) ( Fig. 3c ). Of the 9,045 lead sQTL SNPs, only 42 are also a lead eQTL, suggesting that a substantial fraction of sQTLs are unique and are not detected by standard eQTL analysis.
To further understand the mechanisms underlying sQTLs, we assessed the overlap of sQTLs with SNPs influencing epigenomic marks (xQTLs), such as DNA methylation (mQTL) and histone H3 acetylation on lysine 9 (H3K9ac, haQTL) 29 , that are available from the same DLPFC samples. Indeed, we found that such xQTLs 29 are significantly enriched among sQTLs when compared to randomly selected, matched SNPs (Kolmogorov-Smirnov test P < 0.001): of the lead sQTL, 9% (578) were also associated with an haQTL and 19% (1, 246) were also an mQTL ( Fig. 3d ). This suggests that an important subset of genetic variants co-influences splicing, methylation levels and histone modifications. In a complementary analysis, we found significant sharing of sQTL SNPs among SNPs that also influence histone acetylation (π 1 = 0.74) or methylation (π 1 = 0.82). These overlaps suggest that there is a contribution of epigenomic regulation in splicing.
Given prior reports 21, 30 , we evaluated whether our sQTLs from the aging brain were enriched for Alzheimer's disease susceptibility variants (Fig. 3e ,f). We also assessed enrichment of Alzheimer's disease SNPs (GWAS P < 1 × 10 −5 ) in splicing, methylation or expression QTLs from DLPFC 29 , monocytes 15, 31 , neutrophils 31 and T cells 15, 31 . We found that DLPFC sQTLs are more likely to be enriched for Alzheimer's disease GWAS SNPs, followed by sQTL and eQTL from monocytes (Fig. 3f ). These findings highlight (1) 
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Some of these effects of Alzheimer's disease variants on splicing are known, such as the eightfold increase in full-length CD33 isoform expression 16, 32 , but several of these variants-in CLU, PICALM and PTK2B-have not been previously reported ( Supplementary  Table 10 ). These results delineate the initial events along the cascade of functional consequences for these three Alzheimer's disease variants and provide important mechanistic insights into their development as potential therapeutic targets.
Splicing regulators associated with alternative splicing. Splicing of pre-mRNA is catalyzed by a large ribonucleoprotein complex called the spliceosome, which consists of five small nuclear RNAs and numerous splicing factors 33 . To identify brain splicing factors that regulate sQTL events in trans, we evaluated whether the lead sQTL SNPs that were identified in our study are enriched in RBP binding sites using publicly available cross-linking immunoprecipitation-sequencing (CLIP-seq) datasets from 76 RBPs in CLIPdb 34 . We found that binding targets of 18 RBPs are significantly enriched among lead sQTLs (Fig. 4a ). The most enriched RBP is PTBP1, followed by HNRNPC, CPSF7 and ELAVL1 (P < 0.05, Fisher's exact test with Benjamini-Hochberg correction). Notably, the enrichment for neuronal ELAVL1 RBP target sites is consistent with a recent report that, upon neuronal ELAVL1 depletion, BIN1 and PICALM transcripts were found to have lower exon inclusion for those sites in which ELAVL binding sites directly overlapped with SNPs associated with Alzheimer's disease 35 .
On the other hand, we also observed significant enrichment for the lead sQTL SNPs within the binding sites for a number of heterogeneous nuclear ribonucleoproteins (hnRNP), including hnRNP C (P < 0.009). Furthermore, we find that the expression levels of hnRNP splicing factors are correlated with intronic excision levels of hundreds of genes, many of which are in Alzheimer's disease susceptibility loci including BIN1, PICALM, APP and CLU ( Fig. 4b and Supplementary Figs. 7, 8) . The hnRNP C factor has been linked to Alzheimer's disease in previous studies, including in a recent biochemical study that described the translational regulation of APP mRNA by hnRNP C 36 . This observation goes towards the mechanism of the sQTL: consistent with the assumption that altering the sequence of a binding site changes the likelihood that a splicing event occurs in vivo. In one example of an sQTL that affects intron usage, a SNP within an intron of TBC1D7 is found within CLIP-defined binding sites for hnRNP C as well as other RBPs (Fig. 4c ). Thus, incorporating RBP binding sites as a functional annotation enables us to improve our accuracy when selecting plausible variants that may disrupt binding of splicing factors that cause the alternative-splicing event. Further biochemical studies will be required to understand the full regulatory program that orchestrates the disease-related splicing changes.
Transcriptome-wide association studies prioritize Alzheimer's disease genes. To identify genes for which mRNA expression or alternative splicing is associated with Alzheimer's disease and mediated by genetic variation, we performed two transcriptomewide association studies (TWAS) 37 using either the ROS/MAP expression data or its intronic excision levels as reference panels to reanalyze summary level data from the International Genomics of Alzheimer's Project (IGAP) GWAS 14 . A total of 4,746 genes and 15,013 differentially spliced introns could be analyzed, and we identified 21 genes at FDR < 0.05 for which imputed gene expression or intronic excision levels were significantly associated with 
NATuRe GeNeTiCs
Alzheimer's disease status ( Fig. 5a and Supplementary Table 11 ). Among these, there were genes in known Alzheimer's disease loci including SPI1, CR1, PTK2B, CLU, MTCH2 and PICALM. These results help to pinpoint the likely gene that is the target of the known susceptibility variant in each locus, particularly at the MTCH2 locus in which the functional consequences of the risk allele were unclear. However, the new genes associated with Alzheimer's disease are even more interesting, and eight of these associations are found in loci that showed only suggestive evidence of association in the IGAP study. These genes include AP2A1, AP2A2, FUS, MAP1B, TBC1D7 and others that are now significant at a threshold adjusted for genome-wide testing. This analysis therefore helps to prioritize the long list of suggestive IGAP associations ( Fig. 5a and Supplementary Figs. 9-17 ). Notably, both AP2A1 and MAP1B were recently identified as hub proteins in Alzheimer's disease proteome networks and had lower protein expression levels in brains from patients with Alzheimer's disease compared to those from patients with amyotrophic lateral sclerosis, Parkinson's disease or from control subjects 38 .
To replicate these results, we first assessed whether an expression imputation model built using the CMC dataset 28 yielded similar results when it is deployed in the IGAP GWAS data. We focused on the 21 significantly associated genes described here: four genes (CR1, PTK2B, TBC1D7 and SH3YL1) replicated at FDR < 0.05 and two genes (AP2A1 and PHKB) were suggestive at P < 0.05 with the expression and splicing inference from CMC (Fig. 5b) . The directions of effect for all six associations were consistent in both datasets (Fig. 5b) . Thus, we see replication of our results: they are not due to the unique properties of the ROS/MAP dataset. Second, we used a different Alzheimer's disease GWAS-the UK Biobank (UKBB) GWAS by proxy 39 -to replicate the IGAP TWAS results. We note that, despite analyzing data from 116,196 subjects, the UKBB GWAS is underpowered since the GWAS does not use Alzheimer's disease cases but, rather, subjects who have a first-degree relative with Alzheimer's disease as 'cases' . Nevertheless, we were able to replicate (at a nominal P < 0.05) seven of our IGAP TWAS associations in the UKBB TWAS (Fig. 5c ). These two complementary replication efforts demonstrate the robustness of our results. Finally, we Genes for which there is evidence of significant differential intron usage are highlighted in blue. In green, we highlight those genes for which the TWAS (total gene expression) results are significant. b, Replication of ROS/MAP TWAS in CMC DLPFC data. The red triangles denote genes for which the replication analysis is significant. c, Replication of IGAP Alzheimer's disease TWAS using the UKBB GWAS based on an independent set of subjects. d, PTK2B gene structure (top): clusters of differential splicing events are noted with the colored curves. The panel then zooms to highlight differential intronic usage for chr.8:27,308,412-27,308,560 stratified by rs2251430 genotypes (right). On the left, we show the same data as a box plot. e, Conditional analysis of IGAP GWAS results for two splicing effects for PTK2B and CLU in Alzheimer's disease GWAS data. As noted in the top aspect of the panel, these two Alzheimer's disease genes are located close to one another. The intronic excision events for PTK2B and CLU are present in both ROS/MAP (blue) and in CMC (green) dataset. When the Alzheimer's disease GWAS is conditioned on the PTK2B (chr.8:27,308,412-27,308,560) splicing effect, the CLU effect remained significant, demonstrating its independence from the PTK2B association. The reciprocal analysis conditioning on the CLU (chr.8:27,461,909-27,462,441) effect, the PTK2B association remained significant.
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performed a TWAS using the summary statistics of a meta-analysis of IGAP and UKBB GWAS, and identified three additional genes (ABCA7, RHBDF1 and VPS53) that meet a genome-wide significant threshold in the meta-analysis; ABCA7 is one of the well-validated Alzheimer's disease loci (Supplementary Table 12 ).
Most of the TWAS associations are the result of differential intron usage, suggesting the importance of pre-mRNA splicing in Alzheimer's disease (Fig. 5a ). As an example, a TWAS association with intron usage at PTK2B, a known Alzheimer's disease susceptibility locus, is shown in Fig. 5d . We often observed multiple TWAS-associated genes in the same locus, likely owing to co-expression of genes in close physical proximity or allelic heterogeneity within the susceptibility locus 40 . To account for multiple associations in the same locus, we applied conditional and joint association methods that rely on summary statistics 40, 41 to identify genes that had significant TWAS associations when analyzed jointly (Figs. 5e, 6b) . A region with multiple TWAS associations includes the PTK2B-CLU locus, which shows independent colocalized associations for both GWAS 14 and splicing effects (Fig. 5e ).
Refining known associations is important to translate results into functional studies, but the newly validated Alzheimer's disease genes (Fig. 6a,b ) also offer new insights into disease: we used GeNets 42 to evaluate the connectivity of these new Alzheimer's disease genes with the network of known susceptibility genes that are interconnected by protein-protein interaction (PPI) 43 . These new and known genes associated with Alzheimer's disease susceptibility are directly connected (that is, they form shared 'communities'; P < 0.006) (Fig. 6c ). Furthermore, this joint network is enriched for endocytosis pathways (P < 0.0002), highlighting the existing suggestion that endocytosis pathways are preferentially targeted in Alzheimer's disease. The enrichment for an autophagy-lysosomalrelated pathway (P < 0.003) is more interesting (Fig. 6c ). The genes in the autophagy-lysosomal-related pathway (AP2A2, AP2A1 and MAP1B) form a statistically significant (P < 4.3 × 10 −4 ) PPI subnetwork with known Alzheimer's disease genes (PTK2B, PICALM and BIN1) (Fig. 6d ). This is consistent with prior work that has implicated protein-degradation pathways in Alzheimer's disease 44 . The genes in this network and others not in the network (that is, TBC1D7, PACS2 and RABEP1) are significantly enriched in genes annotated as being involved in endocytosis (blue; P < 0.0002) and autophagy-related pathways (green; P < 0.003). d, The novel Alzheimer's disease genes (AP2A2, AP2A1 and MAP1B) form a significant PPI subnetwork (P < 4.3 × 10 −4 ) with known Alzheimer's disease genes (that is, PICALM, BIN1 and PTK2B).
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Overall, these PPI analyses suggest that our new TWAS-derived genes are not a random set of genes but are part of an Alzheimer's disease network.
Discussion
In this study, we directly examined alternative splicing events in a large dataset of aging brains, which led to the observations that specific alternative splicing events are reproducibly associated with Alzheimer's disease and that certain validated genetic associations affect splicing of a nearby gene as the proximal functional consequence of the susceptibility allele. Our replication efforts demonstrate that the observed Alzheimer's disease-related perturbations in splicing are not simply owing to spliceosomal failure: specific genes are reproducibly affected in a specific manner. Furthermore, results from our in vitro model of tau overexpression in iPSC-derived neurons suggest that perturbation of MAPT may be sufficient to cause at least a subset of the disease-related splicing changes that are observed in the human cortex at autopsy. We used the TWAS approach, which leverages our splicing map and common genetic variants to test the hypothesis that the effect of such variants in Alzheimer's disease is mediated by altering splicing levels. These analyses confirmed many of the known Alzheimer's disease genes (that is, CLU and PTK2B), which supports the role of regulation of splicing levels as key mechanisms in certain loci, but also found several new loci: TBC1D7, AP2A1, AP2A2 and MAP1B (Figs. 5a,6b and Supplementary Figs. 7, 9, 13 ). These new genes reinforce the association of the Clathrin-AP2 adaptor complex with Alzheimer's disease susceptibility 45 . Both AP2A2 and AP2A1 encode components of the AP2 adaptor complex that serves as a cargo receptor, selectively sorting membrane proteins involved in receptor-mediated endocytosis 46 . The AP2 complex and PICALM interact with APP, directing it towards degradation and autophagy 46 .
Our study also offers insights for several well-known Alzheimer's disease loci in which the gene was known but the functional mechanism remained unclear. Similar to our work in CD33 16 , the careful analysis of these cortical data highlights a specific splicing mechanism for the Alzheimer's disease risk alleles at CLU, PICALM and PTK2B. All three are complex proteins with a large number of exons, and our results prioritize specific domains in these proteins that contain the functional domain that influences Alzheimer's disease risk. Furthermore, our analyses of RBPs involved in splicing regulation of Alzheimer's disease susceptibility genes including PICALM, and RNA-binding site analysis of HNRNPC ( Fig. 4c and Supplementary Fig. 6 ) and ELAVL helps to prioritize the variant that may be driving the genetic association and to elaborate the series of events upstream of the susceptibility variant that enable its expression. Thus, the catalog of splicing variants made available with this study provides a starting point for further focused molecular and biochemical experimental validation to fully elucidate the role of these splicing variants in the etiology of Alzheimer's disease.
This study has several limitations. We only characterize splicing events in one region (the DLPFC) of the aging brain. The DLPFC is a region that is affected by amyloid-β pathology relatively early as it spreads throughout the neocortex 47 . The accumulation of tau pathology progresses in a stereotypic manner captured by the Braak stages 48 , and the DLPFC displays accumulation of neurofibrillary tangles containing tau typically when individuals begin to be symptomatic. Thus, both pathological amyloid-β and tau accumulate in the DLPFC in Alzheimer's disease, and we use quantitative measures of these pathologies to enhance our power in discovering the molecular features that are associated with these pathologies. Some of these splicing changes may contribute to the accumulation of pathological amyloid-β or tau whereas others may be a reaction to the presence of pathological amyloid-β or tau accumulation or may be the result of indirect effects of the pathology in other brain regions. Currently, we cannot differentiate these three sources of variation in our results. Expression datasets from multiple brain regions exist in the Genotype-Tissue Expression (GTEx) project 49 , but the sample size is too small (n = 88-136) to build a robust transcriptome model for TWAS. The MSBB has RNA-seq data across three brain regions but owing to the lack of availability for individual level genotypes, we are unable to build reference models from those data. Another limitation of this study is the small sample size of the in vitro experiment; thus, these intriguing results will require testing in a much larger number of iPSC lines to confirm that this effect of MAPT overexpression is generalizable. We note that these MAPT-overexpressing iPSC-derived neurons are functioning normally at the time when they were sampled; thus, these data suggest that at least some of the disease-associated splicing changes that we report may occur very early in the series of molecular events that are caused by perturbation in MAPT expression.
This transcriptome-wide reference map of RNA splicing in the aging cortex is a new resource that highlights strong effects of neuropathology and genetic variation on splicing. It will be useful in annotating the results of genetic and epigenomic studies of neurologic and psychiatric diseases; however, it has an immediate influence on the identification of the functional consequences of several Alzheimer's disease susceptibility alleles, helps to expand the list of loci involved in Alzheimer's disease, and implicates the protein-degradation machinery in the pathology of Alzheimer's disease.
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Methods Study cohorts. ROS. From January 1994 to June 2010, 1,148 individuals agreed to annual detailed clinical evaluation and brain donation at the time of death. Of these, 1,139 have completed their baseline clinical evaluation: 68.9% were women; 88.0% were white, non-Hispanic; their mean age was 75.6 years; and mean education was 18.1 years. There were 287 cases of incident dementia and 273 cases of incident Alzheimer's disease with or without a coexisting condition. Details of the clinical and pathologic methods have been previously reported 17 .
MAP. From October 1997 to June 2010, 1,403 individuals agreed to annual detailed clinical evaluation and donation of the brain, spinal cord, nerve and muscle at the time of death. Of these, 1,372 completed their baseline clinical evaluation: 72.7% were women; 86.9% were white, non-Hispanic; their mean age was 80.0 years; and mean education was 14.3 years with 34.0% with 12 or fewer years of education. There were 250 cases of incident dementia and 238 cases of incident Alzheimer's disease with or without a coexisting condition. Details of the clinical and pathologic methods have been previously reported 51 . To avoid population stratification artifacts in the genetic analyses, the study was limited to non-Hispanic whites.
See Supplementary Note for the details of CMC and MSBB datasets.
Data acquisition, quality control and normalization. Genotyping. DNA from ROS and MAP subjects was extracted from whole blood, lymphocytes or frozen post-mortem brain tissue and genotyped on the Affymetrix GeneChip 6.0 platform at the Broad Institute's Center for Genotyping. Only self-declared non-Hispanic Caucasians were genotyped to minimize population heterogeneity. PLINK software 52 was used to implement our quality-control pipeline. We applied standard quality-control measures for subjects (genotype success rate > 95%, genotype-derived gender concordant with reported gender, excess inter/ intraheterozygosity) and for SNPs (Hardy-Weinberg equilibrium P > 0.001; minor allele frequency> 0.01, genotype call rate > 0.95; misshap test > 1 × 10 −9 ) to these data. Subsequently, EIGENSTRAT 53 was used to identify and remove population outliers using default parameters. Imputation was performed using Michigan Imputation Server with Minimac3 54 using Haplotype Reference Consortium (HRC version r1.1, 2016) 55 panel, which consists of 64,940 haplotypes of predominantly European ancestry. Imputation filtering of r 2 > 0.3 was used for quality control. After quality control, 450 individuals and 8,383,662 genotyped or imputed markers were used for sQTL analysis.
RNA-seq data. RNA was sequenced from the gray matter of the DLPFC of 542 samples, corresponding to 540 unique brains. These samples were extracted using Qiagen's miRNeasy mini kit and the RNase-free DNase Set. RNA was quantified using Nanodrop. The quality of RNA was evaluated by the Agilent Bioanalyzer. All samples were chosen to pass two initial quality filters: RNA integrity (RIN) score > 5 and quantity threshold of 5 μ g (and were selected from a larger set of 724 samples). RNA-seq library preparation was performed using the strand-specific dUTP method with poly-A selection. Sequencing was performed on the Illumina HiSeq with 101-bp paired-end reads and achieved coverage of 150 million reads of the first 12 samples. These 12 samples served as a deep-coverage reference and included two males and two females of non-impaired, mild cognitive impaired and Alzheimer's cases. The remaining samples were sequenced with target coverage of 50 million reads; the mean coverage for the samples to pass quality control is 95 million reads (median 90 million reads). The libraries were constructed and pooled according to the RIN scores such that similar RIN scores would be pooled together. Varying RIN scores result in a larger spread of insert sizes during library construction and leads to an uneven coverage distribution throughout the pool. The RNA-seq data were processed by a parallelized pipeline. This pipeline includes trimming the beginning and ending bases from each read, identifying and trimming adapter sequences from reads, detecting and removing rRNA reads, and aligning reads to the reference genome. Specifically, RNA-seq reads in FASTQ format were inspected using FASTQC program. Barcode and adapter contamination, low-quality regions (8 bp at the start and 7 bp at the end of each FASTQ reads) were trimmed using FASTX-toolkit. To remove rRNA contamination, we aligned trimmed reads to the rRNA reference (rRNA genes were downloaded from the UCSC genome browser selecting the RepeatMask table) by BWA, and we then extracted only paired unmapped reads for transcriptome alignment. STAR (v.2.5) 56 was used to align reads to the transcriptome reference, and RSEM (v.1.3.0) 57 was used to estimate expression levels for all transcripts. To quantify the contribution of experimental and other confounding factors to the overall expression profiles, we used the COMBAT algorithm 58 to account for the effect of batch and linear regression to remove the effects of RIN, postmortem interval, sequencing depth, study index (ROS sample or MAP sample), genotyping principal components, age at death and sex. Finally, only highly expressed genes were kept (mean expression > 2 log 2 fragments per kilobase million), resulting in 13,484 expressed genes for eQTL analysis. The details for cis-eQTL analysis have previously been described 29 .
Intron usage mapping and quantification. We used LeafCutter 20 to obtain clusters of variably spliced introns. LeafCutter enables the identification of splicing events without relying on existing annotations, which are typically incomplete, especially in the setting of large genes or individual-and/or population-specific isoforms. LeafCutter defines 'clusters' of introns that represent alternative splicing choices. To do this, it first groups together introns that overlap (defined by spliced reads). For each of these groups, LeafCutter constructs a graph in which nodes are introns and edges represent overlapping introns. The connected components of this graph define the intron clusters. Singleton nodes (introns) are discarded. For each intron cluster, it iteratively (1) removed introns that were supported by fewer than 100 reads or fewer than 5% of the total number of intronic read counts for the entire cluster, and (2) reclustered introns according to the procedure above. The intron usage ratio for each cluster was next computed and standardized (across individuals) and quantile normalized (across sample) as previously described 20 .
LeafCutter was carefully benchmarked against other methods 20 , and was able to, for example, identify as many or more differentially spliced events when compared to other methods.
Association of intron usage with Alzheimer's disease and neuropathology traits. The association analysis with neuropathology traits and intron usage was performed using a linear model, adjusting for experimental batch, RIN, sex, age at death and postmortem interval. To test for association with Alzheimer's disease, we limited the comparison to those participants with clinical and pathological diagnosis of Alzheimer's disease and those who have neither diagnosis (Supplementary Table 1 ). We used LeafCutter 20 to identify intron clusters with at least one differentially excised intron by jointly modeling intron clusters using a Dirichlet-multinomial generalized linear model 20 . To account for neuronal loss and cell type proportion in each brain sample, we used gene expression level of cell type-specific genes as an additional covariate. However, these measures did not affect our association analysis. We report differentially spliced introns at Bonferroni-corrected P < 0.05 to correct for multiple hypothesis testing.
We used variancePartition 59 to estimate the proportion of variance explained by differently excised introns association with Alzheimer's disease, burden of amyloid, burden of tangles and neuritic plaques. sQTL mapping. We used LeafCutter 20 to obtain the proportion of intron-defining reads to the total number of reads from the intron cluster it belongs to. This intron ratio describes how often an intron is used relative to other introns in the same cluster. We used WASP 60 to remove read-mapping biases caused by allele-specific reads. This is particularly important when a variant is covered by reads that also span intron junctions as it can lead to a spurious association between the variant and intron excision level estimates. We standardized the intron ratio values across individuals for each intron and quantile normalized across introns 61 and used this as our phenotype matrix. We used linear regression (as implemented in fastQTL) 26 to test for associations between SNP dosages (MAF ≥ 0.01) within 100 kb of intron clusters and the rows of our phenotype matrix that correspond to the intron ratio within each cluster. As covariate, we used the first three principal components of the genotype matrix to account for the effect of ancestry plus the first 15 principal components of the phenotype matrix (PSI) to regress out the effect of known and hidden factors. The principal components regress out the technical and biological covariates such as experimental batch, RIN, sex, age at death, and postmortem interval. To estimate the number of sQTLs at any given FDR, we ran an adaptive permutation scheme 26 , which maintains a reasonable computational load by tailoring the number of permutations to the significance of the association. We computed the empirical gene-level P value for the most significant QTL for each gene. Finally, we applied Benjamini-Hochberg corrections to the permutation P values to extract all significant sQTL pairs with an FDR < 0.05.
TWAS.
We used RNA-seq data and genotypes from ROS/MAP to impute the cis genetic component of expression/intron usage 37, 40 into a large-scale late-onset Alzheimer's disease GWAS of 74,046 individuals from the IGAP 14 . The complete TWAS pipeline is implemented in the FUSION suite of tools 40 . The details steps implemented in FUSION are as follows. First, we estimated the heritability of gene expression or intron usage unit and stopped if not significant. We estimated using a robust version of GCTA-GREML 62 , which generates heritability estimates per feature as well as the likelihood ratio test P value. Only features that have a heritability of Bonferroni-corrected P < 0.05 were retained for TWAS analysis. Second, the expression or intron usage weights were computed by modeling all cis-SNPs (± 1 Mb from the transcription start site) using best linear unbiased prediction, or modeling SNPs and effect sizes with Bayesian sparse linear mixed model, least absolute shrinkage and selection operator, Elastic Net and top SNPs 37, 40 . A cross-validation for each of the desired models were then performed. Third, a final estimate of weights for each of the desired models was performed and the results were stored. The imputed unit is treated as a linear model of genotypes with weights based on the correlation between SNPs and expression in the training data while accounting for linkage disequilibrium (LD) among SNPs. To account for multiple hypotheses, we applied an FDR < 0.05 within each expression and splicing reference panel that was used.
We used the same TWAS pipeline to process the CMC datasets (see Supplementary Note).
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Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No allocation into groups was performed. Participants of the ROS and MAP studies were not cognitively impaired at enrollment. After death, pathological assessment was performed to measure tau, tangles, and amyloid-beta burden. Subsequently, brain samples were sent to RNA-sequencing in an arbitrary order.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Individuals generating the brain-derived RNA-sequence data were blinded to the outcome measures.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Calling local splicing events or intronic excision: LeafCutter, http:// davidaknowles.github.io/leafcutter/index.html RNA-seq aligner: STAR v2.5, https://github.com/alexdobin/STAR Quantifying gene expression: RSEM v1.3.0, https://github.com/deweylab/RSEM Mapping QTL: fastQTL, http://fastqtl.sourceforge.net/ Allele-specific read mapping: WASP, https://github.com/bmvdgeijn/WASP Removing batch effects from RNA-seq data: COMBAT, https://www.bu.edu/jlab/ wp-assets/ComBat/Abstract.html Genotype, genetic association and QC: PLINK, https://www.cog-genomics.org/ plink2 Population stratification: EIGENSTRAT, https://github.com/DReichLab/EIG/tree/ master/EIGENSTRAT Imputing GWAS data: Michigan Imputation Server, https:// imputationserver.sph.umich.edu/index.html Transcriptome-wide associaiton study,Performing the expression imputation using several learning models, joint/conditional analysis: FUSION, http://gusevlab.org/ projects/fusion/ Heritability estimates, GCTA-GREML, http://cnsgenomics.com/software/gcta/ #Overview Quantitates the expression level of alternatively spliced genes: MISO, http:// genes.mit.edu/burgelab/miso/; Evaluate enrichment of trait-associated variants in annotated features: GREGOR, http://genome.sph.umich.edu/wiki/GREGOR; GWAS analysis of regulatory or functional information enrichment with LD correction: GARFIELD, http://www.ebi.ac.uk/birney-srv/GARFIELD; Figures were generated using FUSION tools, R and ggplot2 2.2.1.
